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Objective: To compare two transient models of synovitis-osteoarthritis (OA) in horses by characterizing
biological changes in synovial ﬂuid and joint tissue.
Method: Twelve skeletally mature mares were utilized in a block design. Synovitis was induced by an
intra-articular injection of 100 ng recombinant equine interleukin 1 beta (reIL-1b) or 0.5 ng lipopoly-
saccharide (LPS) into a middle carpal joint in 1 ml volumes. One ml of saline was injected into the contra-
lateral control joint. Lameness evaluations were conducted through post-injection hour (PIH) 8 (at which
time arthroscopic removal of synovium and articular biopsies was done), and at PIH 240. Arthrocentesis
collection of synovial ﬂuid occurred between PIH 0 and 48. An arthroscopic examination at PIH 8
included synovium and articular cartilage biopsies for gene expression analysis.
Results: Synovial ﬂuid analysis indicated that single injections of reIL-1b or LPS increased synovial white
blood cell (WBC), neutrophil count, total protein, prostaglandin E2 (PGE2) concentrations and general
matrix metalloproteinase (MMP) activity relative to control joints through PIH 8. Injections of either reIL-
1b or LPS increased mRNA expression for MMP-1 and a disintegrin and metalloprotease with throm-
bospondin motifs (ADAMTS)-4 in synovium and for MMP-1, ADAMTS-4, ADAMTS-5 in articular cartilage
collected at PIH 8 compared to saline injections.
Conclusion: Injections of reIL-1b into equine carpal joints resulted in a transient inﬂammatory response
that was similar in severity to the LPS injection, causing increased expression of certain deleterious
mediators in joint tissues at 8 h. Given that IL-1b is a known critical mediator of traumatic arthritis and
OA, this humane and temporary model may be useful in evaluating therapeutics that act against early
stages of joint disease.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Synovitis is a key factor in the pathophysiology of osteoarthritis
(OA) in humans1 and horses2. The development of OA associated
with synovitis is likely due to persistent upregulation of mediators
that contribute to articular cartilage degradation including matrix
metalloproteinases (MMPs), a disintegrin andmetalloproteasewith
thrombospondin motifs (ADAMTS) and prostaglandin E2 (PGE2)2.
The cytokine interleukin-1b (IL-1b), which is prevalent in equine2,3
and human4e6 OA, stimulates production of MMPs and PGE24.
IL-1b’s importance in the OA cascade has been demonstrated by itsC.W. McIlwraith, Gail Holmes
University, Fort Collins, CO
38.
C.W. McIlwraith).
s Research Society International. Pinhibition signiﬁcantly reducing OA in well-established equine
osteochondral fragment3 and canine anterior cruciate ligament7
models.
There are several similarities between horses and humans when
considering OA. Both experience naturally occurring OA, due
primarily to traumatic injury. The ability of inﬂammation to
produce early signs of OAwas demonstrated in horses over 30 years
ago8. Given the importance of synovitis in the pathogenesis of OA,
equine experimental models for inducing joint inﬂammation,
including amphotericin, carrageenan, polyvinyl alcohol foam
particles and blood, have been evaluated. The endotoxin lipopoly-
saccharide (LPS) from Escherichia coli bacteria is known to induce
acute synovitis resembling septic arthritis, and has been used as
a model9e14 to evaluate treatments for acute synovitis15e20. The
role of IL-1b in the natural inﬂammatory cascade makes it a more
appropriate model for evaluating the pathobiology of OA; however,ublished by Elsevier Ltd. All rights reserved.
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studies have induced inﬂammation using intra-articular injections
of recombinant human IL-1b (rhIL-1b)21,22, reporting increased
synovial white blood cells (WBCs) and total protein levels. Also,
gene expression changes in rat joints following intra-articular
injection of rat IL-1b have been reported23. While these studies
suggest intra-articular injection of IL-1b is suitable for evaluating
OA pathobiology, a comprehensive proﬁle of changes in both
synovial ﬂuid and articular tissue has not been done. Additionally,
the effect of recombinant equine IL-1b (reIL-1b) has not been
evaluated in vivo despite in vitro studies demonstrating a potent
degradative response in articular cartilage explants at concentra-
tions as low as 0.1 ng/ml24. Therefore, we hypothesized that a single
injection of reIL-1b causes, (1) inﬂammatory changes in equine
synovial ﬂuid that are similar to LPS, and (2) gene expression
changes in joint tissue that closely mimic early clinical OA.
Methods
Experimental design and induction of temporary carpal synovitis
Twelve healthy mares with clinically normal carpal joints,
determined by radiographic evaluation, were blocked by age
(mean¼ 9.8 years old), weight (mean¼ 540 kg) and body condition
score25 (mean ¼ 7), and randomly assigned into LPS (n ¼ 6) or reIL-
1b (n ¼ 6) treatment groups. With the exception of the ﬁrst author,
all investigators and staff were blinded to the study.
Intra-articular injections were administered to the middle carpal
joint in 1 ml volumes. At post-injection hour (PIH) 0, the LPS group
received 0.5 ng LPS (from E. coli 055:B5; SigmaeAldrich) in sterile
phosphate buffered saline (PBS). The reIL-1b group received 100 ng
of reIL-1b (R&D Systems) in sterile PBS. The reIL-1b dose has been
previously used in in vivo26 and in vitro24 models to elicit measur-
able inﬂammatory responses. As a control, each horse received an
injection of sterile PBS into the contra-lateral carpal joint.
Evaluation of clinical response to treatment
Lameness measurements were conducted at PIH 0, 4, 8 and 240
using the American Association of Equine Practitioners grading
scale27. Horses were monitored throughout the study for signs of
discomfort. Temperature, pulse, and respiration at rest were
measured every 2 h through PIH 8; every 4 h through PIH 16, and at
PIH 24 and PIH 48.
Synovial ﬂuid collection
Synovial ﬂuid was aseptically aspirated at PIH 0, 4, 8, 24 and 48.
A portion of the ﬂuid was processed for cytology (WBC count, cell
differential and total protein). The remaining volume was centri-
fuged, and the supernatant was stored at 80C until analyzed.
Arthroscopic biopsy procedure
At PIH 8, all horses underwent arthroscopic surgery on treated
and control joints to obtain synovium and articular cartilage
samples. Approximately 6 mg wet weight samples of both tissues
were placed in 500 ml of TRIzol reagent (Invitrogen, Carlsbad, CA),
ﬂash frozen in liquid nitrogen and then stored at 80C until
analyzed.
Synovial ﬂuid analysis
Synovial ﬂuid WBC and total protein concentrations were
determined using a Coulter T6e60 automated cell counter andrefractometry. Differential neutrophil values were evaluated using
cytospin and direct smear analysis.
Synovial ﬂuid samples were evaluated for PGE2, general MMP
activity and glycosaminoglycan (GAG) concentrations. Samples
were analyzed in triplicate.
SynovialﬂuidPGE2was isolatedbysolid-phaseextractionusingC2
ethylmini-columns(AgilentTechnologies;Wilmington,DE), followed
by quantiﬁcation using a commercially available Enzyme-linked
immunosorbent assay (ELISA) kit (Assay Designs; Ann Arbor, MI).
Total MMP activity was determined based on cleavage of
substrate FS-6 (Calbiochem, San Diego, CA), which has been vali-
dated for equine synovial ﬂuid13. Negative controls that inhibited
MMP activity were createdwith 10mM ethylenediaminetetraacetic
acid (EDTA). An EDTA-free protease inhibitor (complete, Roche
Diagnostics GmbH; Mannheim, Germany) was used as a positive
control to eliminate non-MMP enzymatic activity. Samples were
aliquoted into black microplates, and ﬂuorescence was read at
excitationmax 324 and emissionmax 400, every 5 min for 20 min.
General MMP activity was determined by linear slope of increasing
ﬂuorescence with time, and expressed as a rate of FS-6 conversion
per second (RFU/sec).
Total GAG concentrations were measured spectrophotometri-
cally using a modiﬁed 1,9-dimethylmethylene blue dye-binding
assay used previously in our laboratory28.
Quantitative reverse transcriptase polymerase chain reaction (qRT-
PCR) of joint tissues
Cartilage samples were thawed, added to TRIzol reagent, and
then pulverized. Synovial membrane samples were homogenized
on ice for 30 s and mixed with TRIzol. To isolate RNA, a chloroform
extraction procedure, previously used for joint tissue29, was per-
formed. Nucleic acid concentrations were determined using the
ND1000 spectrophotometer at 260/280 nm. Samples with 260/280
ratios less than 1.7 were further puriﬁed using the RNeasy Mini Kit
(Qiagen, Chatsworth, CA) according to manufacturer’s instructions.
RNA was reverse transcribed to cDNA using Superscript III cDNA
synthesis kit (Invitrogen, Carlsbad, CA). Primer/probes were mixed
with TaqMan Gene Expression Master Mix (Applied Biosystems,
Foster City, CA) and cDNA, and semi-quantitative real-time PCRwas
performed on an ABI Prism 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA). Primer/probes for ADAMTS-4,
ADAMTS-5, MMP-1, MMP-13, IL-1b, tumor necrosis factor-alpha
(TNF-a) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(Table I) were designed and validated at the authors’ institution.
Primer/probes for cyclooxygenase-2 (COX-2) were purchased from
the University of California-Davis’s Lucy Whitter Molecular Core
Facility (Davis, CA). Samples were analyzed in duplicate with
expression normalized to the housekeeping gene GAPDH. Expres-
sion of each genewas calibrated to the average expression in the LPS
control joints and reported as fold change relative to LPS controls.
Statistical analysis
Sample size was determined using SAS 9.2 statistical software
(SAS Institute, Inc., Carey, NC) and data from previous research that
measured synovial ﬂuid total protein from horses that received
LPS10, IL-1b22 or saline22. A sample size of 6 per treatment group
provided a statistical power of 0.90 (a ¼ 0.05) as calculated using
one-way analysis of variance (ANOVA). WBC, neutrophil cell count,
and PGE2 data were log transformed to standardize variance. All
clinical and synovial ﬂuid data were compared using ANOVA for
repeated measures. Between-subject effects were treatment and
joint with time being the repeated measures effect. Signiﬁcance
level was set at P  0.05; differences were further analyzed using
Table I
Primers and probes used for semi-quantitative real-time PCR
Target gene PCR primers PCR probe
GAPDH Forward-AAGTGGATATTGTCGCCATCAAT
Reverse-AACTTGCCATGGGTGGAATC
TGACCTCAACTACATGGTCTAGTTTCA
ADAMTS-4 Forward-TGTGATCGTGTCATTGGCTCC
Reverse-TGTTTGCTGCAGCTAGAACCATC
AGTTTGACAAGTGCATTGGTGTGCGGT
ADAMTS-5 Forward-AAGGTGACTGATGGGACCGAATGT
Reverse-TTTGAGCCAATGATGCCGTTCACAG
AGGCCATACAGTAATTCCGTCTGCGT
MMP-1 Forward-ACTGCCAAATGGACTTCAAGCTGC
Reverse-TCTTCACAGTGCTAGGAAAGCCG
CAGGATGTGCTCTACGGATACCCCAAGGAC
MMP-13 Forward-TGATGAAACTTGGACAAGCAGTTCC
Reverse-CCTTGGAGTGGTCGAGACCTAAG
AGGCTACAACTTGTTTCTTGTCGCTGCACAC
TNF-a Forward-AGTGACAAGCCTGTAGCCCATGTT
Reverse-ATGAGGTACAGCCCATCCAATGGT
AATGGCGTGAAGCTGACAGACAACCA
IL-1b Forward-AGTCTTCAGTGCTCAGGTTTCTGA
Reverse-TGCCGCTGCAGTAAGTCATC
CAGCCATGGCAGCAGTACCCGA
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mean  95% conﬁdence interval.
Results
Clinical response to intra-articular injection
All horses were free of lameness (Fig. 1) prior to injection. By
PIH 4 lameness was higher in all treated limbs (reIL-1b: 3.7  0.39;
LPS: 3.8  0.39) compared to baseline measurements (P < 0.001),
which continued through PIH 8. Injections of PBS in the contra-
lateral control joints did not result in lameness. Lameness evalua-
tions were not performed at PIH 24 and 48 due to surgery, but
at those time points all horses were bearing weight on limbs
and walking comfortably. All horses were clinically sound 240 h
post-injection.
Synovial ﬂuid analysis
The volume of aspirated synovial ﬂuid was signiﬁcantly higher
(P < 0.0001) in treated joints (4.49  0.46 ml) than in control joints
(2.87  0.46 ml). Baseline measurement of synovial ﬂuid WBCs
[Fig. 2(A)] were similar among all horses and within normal
ranges30. Neutrophil values [Fig. 2(B)] at baseline differed amongstFig. 1. Clinical response to intra-articular injection of reIL-1b (100 ng), LPS (0.5 ng) or
PBS on lameness grade. Columns lacking common letters indicate signiﬁcant differ-
ences across both treatments (reIL-1b, LPS) and time points (P < 0.0001). *Indicates
time point when arthroscopic biopsy was performed. Data are displayed as
means  95% conﬁdence intervals.horses; therefore, data were adjusted with baseline values as
covariates. At baseline, two horses had signiﬁcantly higher
neutrophil values in treated joints compared to the remaining
treated joints; however, baseline values were less than 1% of values
obtained following treatment at PIH 4. In control joints, WBC
concentrations were signiﬁcantly different between reIL-1b
(12,800  21,447 cells/ml) and LPS joints (1,000  21,447 cells/ml)
at PIH 8 (P ¼ 0.001); Injections of reIL-1b or LPS resulted in
a signiﬁcant increase in WBC count at PIH 4 (reIL-1b:
134,300  19,581 cells/ml; LPS: 143,283  19,582 cells/ml) and 8
(reIL-1b:170,700  37,581 cells/ml; LPS: 234,833  19,582 cells/ml),
respectively when compared to PBS control joints (P < 0.001) at
similar time points [Fig. 2(A)]. At PIH 24 and 48, WBC concentra-
tions in treated joints were not signiﬁcantly different between reIL-
1b and LPS. A rise in neutrophils occurred in all joints above
baseline values, with treated joints having signiﬁcantly higher
values compared to control joints (P< 0.01) [Fig. 2(B)]. Total protein
[Fig. 2(C)], within normal levels31 prior to IA injections, was
elevated signiﬁcantly over baseline values at PIH 4 (reIL-1b:
5.11  0611 g/dl; LPS: 5.45  0.61 g/dl), PIH 8 (reIL-1b: 6.1  0.61 g/
dl; LPS: 6.32  0.61 g/dl), PIH 24 (reIL-1b: 5.96  0.61 g/dl; LPS:
6.38  0.61 g/dl) and PIH 48 (reIL-1b: 4.96  0.61 g/dl; LPS:
5.08  0.61 g/dl) in all treated joints (P < 0.05). Synovial ﬂuid total
protein levels in control joints, regardless of treatment, increased
over time with concentrations peaking at PIH 24 (reIL-1b:
5.28  0.61 g/dl; LPS: 5.66  0.61 g/dl).Synovial ﬂuid biomarkers
Synovial PGE2 concentrations [Fig. 3(A)] did not differ among
horses at PIH 0. Injection of reIL-1b or LPS increased PGE2
concentrations (reIL-1b: 1,952  357 pg/ml; LPS: 2,244  450 pg/
ml) over control joints (reIL-1b: 37  357 pg/ml; LPS: 33  330 pg/
ml) by PIH 4 (P < 0.01). PGE2 levels remained elevated through PIH
48 in all treated joints. Joints treated with reIL-1b had signiﬁcantly
higher PGE2 levels than LPS-treated joints at PIH 24 (P ¼ 0.011)
(reIL-1b: 748  329 pg/ml; LPS: 316  329 pg/ml) and PIH 48 (reIL-
1b: 220  329 pg/ml; LPS: 73  329 pg/ml), respectively
(P ¼ 0.001).
Synovial MMP activity [Fig. 3(B)] was similar among all horses
at PIH 0. Repeated ﬂuid aspiration did not signiﬁcantly change
MMP activity in control joints. Synovial ﬂuid from both treated
groups demonstrated signiﬁcantly higher MMP activity (reIL-b:
0.37  0.13 D RFU/s; LPS: 0.44  0.13 D RFU/s) compared to control
joints at PIH 4 (reIL-b: 0.06  0.14 D RFU/s; LPS: 0.06  0.13 D RFU/
s) (P < 0.0001). Levels were also signiﬁcantly higher in treated
joints (reIL-b: 0.61  0.13 D RFU/s; LPS: 0.53  0.13 D RFU/s)
Fig. 3. Synovial ﬂuid response to intra-articular injection of reIL-1b (100 ng), LPS
(0.5 ng) or PBS. (A) PGE2 concentration: columns lacking common letters indicate
signiﬁcant differences across treatments (reIL-1b, LPS), joints (treated, control), and
time points (P < 0.01). (B) General MMP activity: columns lacking common letters
indicate signiﬁcant differences across joints (treated, control), and time points
(P < 0.0001). (C) Glycoaminoglycan concentration: columns lacking common letters
indicate signiﬁcant differences across time points (P < 0.0001); signiﬁcant difference
over time across joints (P ¼ 0.051). *Indicates time point when arthroscopic biopsy was
performed. Data are displayed as means  95% conﬁdence intervals.
Fig. 2. Cytology evaluation of synovial response to intra-articular injection of reIL-1b
(100 ng), LPS (0.5 ng) or PBS. For each outcome, columns lacking common letters
indicate signiﬁcant differences across treatments (reIL-1b, LPS), joints (treated, control),
and time points. (A) WBCs (P < 0.01). (B) Neutrophils (P < 0.01). Neutrophil values at
baseline differed among groups; therefore data were adjusted with PIH 0 values as
covariates. (C) Total protein (P < 0.0001). *Indicates time point when arthroscopic
biopsy was performed. Data are displayed as means  95% conﬁdence intervals.
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0.11  0.13 D RFU/s) at 8 h post-injection (P < 0.0001). There were
no signiﬁcant differences between reIL-1b and LPS groups at any
time point.Synovial ﬂuid GAG levels [Fig. 3(C)] were similar in all joints
prior to injections, and remained similar through PIH 8. However,
GAG levels, regardless of joint or treatment, increased at PIH 24,
and remained elevated through PIH 48 (P < 0.001).
Fig. 5. Effect of single intra-articular injection of reIL-1b (100 ng), LPS (0.5 ng) or PBS
(controls) on cartilage gene expression at 8 h post-injection. Values expressed as fold
difference relative to LPS controls. (A) MMP-1: columns lacking common letters
indicate a signiﬁcant difference between joints (P ¼ 0.002). (B) ADAMTS-4: columns
lacking common letters indicate signiﬁcant difference between joints (P < 0.0001) and
treatments (P ¼ 0.054). (C) ADAMTS-5: columns lacking common letters indicate
signiﬁcant difference between joints (P ¼ 0.002). Data are displayed as means  95%
conﬁdence intervals.
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Synovium
Synovial tissue gene expression of MMP-13, ADAMTS-5, TNF-a,
and COX-2 did not differ signiﬁcantly among treated and control
joints. There was a signiﬁcant difference between LPS and reIL-1b
tissues compared to controls for MMP-1 (59-fold increase)
(P ¼ 0.011) and ADAMTS-4 (13-fold increase) (P < 0.0001) [Fig. 4(A
and B)]. Expression of synovium IL-1b mRNA [Fig. 4(C)] in treated
joints was 5.5-fold higher than control tissues (P¼ 0.003) with LPS-
treated joints having a 2-fold higher expression than reIL-1b
(P ¼ 0.038).
Articular cartilage
Gene expression of MMP-13 and TNF-a was not signiﬁcantly
different among treated and control joints (P ¼ 0.18). There was
a signiﬁcant difference between LPS and reIL-1b tissues compared
to controls for MMP-1 (223-fold increase) (P ¼ 0.002) and
ADAMTS-5 (3-fold increase) (P ¼ 0.002) [Fig. 5(A and C)]. Expres-
sion of ADAMTS-4 [Fig. 5(B)] was 2.9-fold higher in LPS-treated
cartilage vs reIL-1b (P ¼ 0.054) with treated joints 20-fold higher
compared to control joints (P < 0.0001). Expressions of IL-1b and
COX-2 in control cartilages were not consistently within the
detectable limit of the assay; therefore, these data were not
analyzed. In cartilage from LPS joints, expression of IL-1b and COX-2
were 3.4- and 3.9-fold higher in cartilage from reIL-1b joints,
respectively.
Discussion
The development of reversible in vivo models of synovitis is
valuable for studying OA pathophysiology, and testing therapeutic
modalities. The horse is an excellent translational model for eval-
uating OA treatments3 with outcomes relevant to human OA. The
use of the endotoxin LPS has been an effective model for inducing
joint inﬂammation11,12,16 and has been the primary agent used for
in vivo, non-terminal equine studies. Comparative studies with
other models are lacking, and little information is available
regarding reIL-1b’s ability to induce predictable inﬂammation in
the joint. The reIL-1b product has only recently become availableFig. 4. Effect of single intra-articular injection of reIL-1b (100 ng), LPS (0.5 ng) or PBS
on synovium gene expression at 8 h post-injection. Values expressed as fold difference
relative to LPS controls. (A) MMP-1 expression: columns lacking common letters
indicate a signiﬁcant difference between joints (P ¼ 0.011). (B) ADAMTS-4 expression:
columns lacking common letters indicate a signiﬁcant difference between joints
(P < 0.0001). (C) IL-1b gene expression: columns lacking common letters indicate
signiﬁcant difference between joints (P ¼ 0.003) and treatments (P ¼ 0.038). Data are
displayed as means  95% conﬁdence intervals.and the in vivo use of intra-articular reIL-1b has only been reported
once26 with results limited to deﬁning inﬂammatory effects.
Therefore, this study was aimed at comparing reIL-1b to LPS as an
in vivo synovitis model and exploring the potential of reIL-1b as
a reversible model of OA.
The AAEP lameness scoring system27 is a clinical standard for
classifying degrees of equine musculoskeletal injury and pain. The
absence of lameness in the PBS-injected joints illustrated that it
was the intra-articular injection of LPS or reIL-1b that induced
lameness. The lameness in horses treated with LPS was consistent
with other studies that utilized a single dose of 0.5 ng LPS11,13.
Furthermore, 100 ng reIL-1b and 0.5 ng LPS resulted in a similar
degree of lameness, indicating reIL-1b is equally sufﬁcient as LPS for
inducing clinical signs of lameness.
A strong intra-articular inﬂammatory response in treated joints
was demonstrated by signiﬁcant increases in synovial WBC,
neutrophil counts and total protein between PIH 4e48, which was
consistent with previous studies using exogenous LPS11e14, rh
IL-1b21,22. In control joints, a signiﬁcant increase in WBC concen-
trations at PIH 8, neutrophil counts at PIH 4, and total protein at PIH
4 are considered to be reﬂective of repeated arthrocentesis, which
is consistent with other studies12,21. The response to PBS was much
less profound than that to LPS and reIL-1b. Notably, at PIH 8, 6 ml of
synovial ﬂuid was easily aspirated from joints injected with LPS or
reIL-1b, and it was difﬁcult to get more than 1 ml from control
joints.
Synovial PGE2 concentrations were elevated from intra-articular
injections of reIL-1b or LPS but not PBS. These results are consistent
with previous studies using LPS12,13 or rhIL-1b21,22. In addition,
PGE2 levels remained elevated in treated joints through PIH 48
when compared to baseline values; these ﬁndings differ from
others using similar concentrations of LPS13 or rhIL-1b22. Hawkins
and others12 reported a comparable prolonged elevation in PGE2
(beyond 8 h post-injection) to what was reported here; however,
the LPS dosage (1.5 mg) was higher than in the present study.
Although one could expect the sustained PGE2 concentrations in
our study to reﬂect a secondary response due to surgery at PIH 8,
PGE2 levels in reIL-1b control joints did not change signiﬁcantly
from baseline post-surgery (PIH 24e48) with surgical
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injection of 100 ng of reIL-1b is adequate in stimulating in vivo
PGE2 production to levels that reﬂect an inﬂammatory response.
MMP activity in synovial ﬂuid followed a similar pattern as
PGE2; joints treated with reIl-1b or LPS exhibited increasing levels
to PIH 8, and decreasing by PIH 24. While an increase in MMP
activity was observed at PIH 48 in reIL-1b treated joints, this
increase was not at the magnitude seen at PIH 4, nor was it
signiﬁcantly different from LPS-treated joints at the same point in
time. Synovial ﬂuid collection did not resume until 16 h after
surgery; therefore, it is unknown if the difference in MMP activity
in treated joints is a result of treatment, effect of surgery or lag in
time between collections. This was the ﬁrst time arthroscopic
biopsy had been introduced to either model so this requires further
evaluation. Repeated aspiration did not alter MMP activity as
evident by lack of signiﬁcant change in control joints throughout
the experimental period. These ﬁndings were in contrast to van den
Boom and others32 who reported subsequent arthrocenteses
increased MMP activity in unstimulated joints within 12 h.
However, in that study, half of the horses were subjected to daily
exercise; horses used in the current study were sedentary. Despite
multiple collections, an intra-articular injection of 1 ml of PBS and
repeated aspiration did not cause a signiﬁcant change in MMP
activity in control joints. The data presented here are the ﬁrst to
demonstrate reIL-1b’s ability to instigate general MMP activity in
the live animal, indicating reIL-1b potential as a method for
investigating inﬂammatory processes associated with early stages
of OA.
In the current study, the arthroscopic surgical procedure at PIH 8
may have inﬂuenced MMP activity and GAG concentrations
measured post-surgery. An increase in GAG concentrations in
control and treated joints is speculated to be a consequence of the
biopsy procedure rather than repeated aspiration or treatment
application. It is unknown whether the overall change in GAG
concentration is a reﬂection of increased synthesis or increased
degradation. This could be clariﬁed with the evaluation of addi-
tional anabolic and catabolic markers.
Synovial membrane and articular cartilage biopsies showed that
intra-articular injection of LPS or reIL-1b upregulated gene
expression of certain catabolic enzymes associated with OA. The
increase inMMP-1 expressionwith LPS or reIL-1b is consistent with
ex vivo stimulation of chondrocytes33. To our knowledge, this study
is the ﬁrst to report in vivo upregulation of MMP-1 expression in
equine joint tissue.
Intra-articular injection of reIL-1b or LPS induced greater
expression of ADAMTS-4, but not ADAMTS-5, in synovial
membrane compared to control joints. These ﬁndings are consis-
tent with ADAMTS-4 and ADAMTS-5 expression in human OA
synovium34. Articular cartilage expression of ADAMTS-4 and
ADAMTS-5 is consistent with other equine35 and human36 OA
models, yet differs from murine OA models in which ADAMTS-5
was the primary aggrecanase in cartilage degradation37. Discrep-
ancies between human and murine models have been reported36
presenting a challenge in comparing ﬁndings in those species.
However, signiﬁcant expression of ADAMTS-5 in cartilage, but not
in synovial tissue in the present equine study is similar to what has
been reported in human studies (as reviewed)38 indicating poten-
tial similarities in expression of aggrecanases between these two
species.
The increase in IL-1b expression in LPS-treated synovium
compared to reIL-1b treated joints may indicate an LPS-stimulated
endogenous production of IL-1b. It is unclear if the lower expres-
sion of IL-1b in reIL-1b treated synovium is due to a lack of or
minimal endogenous IL-1b production at PIH 8 that follows reIL-1b
injection. Previous in vitro studies have reported LPS-induced IL-1bproduction in humanOA synovial tissue and cartilage39,40; however
measurements were of protein concentrations and not gene
expression. Exogenous IL-1b is rapidly cleared from the joint and
does not stimulate endogenous production of IL-1b21, possibly
allowing for a more representative evaluation of mediator response
to IL-1b. Concentrations of IL-1b in synovial ﬂuid were not evalu-
ated in the present study; therefore, it is unknown if and to what
extent endogenous IL-1b production may have occurred in treated
joints.
Upregulation of chondrocyte expression of ADAMTS-4 in LPS
joints compared to reIL-1b joints may be due to endogenous
cytokine production stimulated by LPS injection; however, synovial
ﬂuid biochemical analysis did not differ between LPS and reIL-1b.
The inﬂammatory response to LPS is characterized by an initial
release of the cytokines IL-1 and TNF-a4e6,41, and is followed by
a release of PGE212,13,17 and MMPs13. The two forms of IL-1 found in
the horse are IL-1a and IL-1b42. Both have been cloned and evalu-
ated for stimulatory effect in vitro, and act through the same
receptor, but equine IL-1b is more potent for stimulating PGE2 than
equine IL-1a24. The present study is the ﬁrst to demonstrate that an
injection of exogenous reIL-1b resulted in signiﬁcant increases in
PGE2 and general MMP activity.
To our knowledge, we report the ﬁrst in vivo investigation of
equine joint tissues in response to LPS or reIL-1b injections. The
tissue amounts collected through biopsy procedures were sufﬁ-
cient for evaluating mRNA expression with no permanent clinical
signs consistent with morbidity to the defects. It is to be noted that
the horses were not euthanized, a practice often required in other
animal models23. These ﬁndings further validate the role of syno-
vitis in the generation of MMPs and aggrecanases that are associ-
ated with OA, and that MMP-1 and ADAMTS-4 may be therapeutic
targets.
A limitation to this reIL-1b synovitis model is that the injection
of reIL-1b overrides potential upstream regulators of IL-1b
synthesis in the natural disease process. However, given that
inhibitors of IL-1b have shown a strong ability to modulate cartilage
degradation in experimental OA models41,7, we feel that this model
has great promise for identifying therapeutics that can signiﬁcantly
impact the progression of OA. The absence of protein measure-
ments for synovial IL-1b restricts our interpretation of LPS-
stimulated cytokine activity, although based on gene expression
analysis it appears LPS could stimulate IL-1b protein synthesis. The
inﬂammatory response was similar between reIL-1b and LPS, as
expected. LPS activates IL-1b which further stimulates eicosanoid
production and MMP activity. Additionally, the reaction by the
synovial membrane is non-speciﬁc2. Synovitis is related to acute
stimulus rather than a speciﬁc cause.
We administered 100 ng of reIL-1b as we believed that this dose
would induce a robust inﬂammatory response that was temporary
and not severe enough to require rescue analgesic, and had been
the reIL-1b dose used in a previous in vivo study26. While a reIL-1b
dose of 0.1 ng/ml was reported to stimulate GAG release from
equine cartilage explants24 in vitro, a 6-fold increase in PGE2 release
was reported in the same study for 10 ng/ml of reIL-1b. Given that
PGE2 release is an important outcome measure for models of
synovitis, our dose was intended to stimulate robust PGE2 release
based on an estimated joint volume of 10 ml, resulting in a reIL-1b
concentration of 10 ng/ml upon injection. We conﬁrmed lameness
scores consistent with a robust yet humane inﬂammatory response.
Additional studies would be needed to determine if a reIL-1b dose
less than 100 ng/ml could stimulate an inﬂammatory response that
can be detected by changes in ﬂuid biomarkers and tissue gene
expression.
In this study, we characterized changes in synovial ﬂuid and
tissue following intra-articular injection of reIL-1b that were found
T.N. Ross et al. / Osteoarthritis and Cartilage 20 (2012) 1583e1590 1589to be consistent with known pathogenesis of OA, and are similar to
the cellular response of acute synovitis commonly reported in
equine OA. While the degree of inﬂammation may be reﬂective of
sepsis or human rheumatoid arthritis, the response was short and
temporary. With regard to the use of the contra-lateral joint as
a control, it is to be noted that there was no increase in MMP and
PGE2 levels in those joints but there was an increase in white cell
and GAG levels. Clarifying whether these changes were due to
a systemic effect or to injection of saline would require a separate
group of horses to be used as controls. The methods introduced in
this study produced a synovitis response in horses that were
temporary and reﬂective of OA, supporting the use of the horse as
a translational model for studying OA.
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